Lexicon Pharmaceuticals | LXRX - Cost Of Sales


Lexicon Pharmaceuticals reported $201K in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 4.92B 535M Dec/2025
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Illumina USD 400M 49M Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 8.07B 103M Mar/2026
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
MannKind USD 33.65M 13.44M Dec/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Novartis USD 3.54B 3M Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Thermo Fisher Scientific USD 7.58B 674M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024